Modality
ADC
MOA
C5i
Target
KRASG12C
Pathway
PD-1/PD-L1
FSGSMesoADHD
Development Pipeline
Preclinical
~May 2019
→ ~Aug 2020
Phase 1
~Nov 2020
→ ~Feb 2022
Phase 2
May 2022
→ Jan 2030
Phase 2Current
NCT03304152
1,397 pts·ADHD
2022-11→2029-11·Completed
NCT08874452
999 pts·FSGS
2022-05→2030-01·Not yet recruiting
2,396 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-11-163.6y awayPh3 Readout· ADHD
2030-01-093.8y awayPh3 Readout· FSGS
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030
P2/3
Not yet…
P2/3
Complet…
Catalysts
Ph3 Readout
2029-11-16 · 3.6y away
ADHD
Ph3 Readout
2030-01-09 · 3.8y away
FSGS
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03304152 | Phase 2/3 | ADHD | Completed | 1397 | HbA1c |
| NCT08874452 | Phase 2/3 | FSGS | Not yet recr... | 999 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| VRT-1891 | Vertex Pharma | Phase 1 | KRASG12C | |
| Pemitapinarof | BeiGene | Approved | KRASG12C | |
| ITC-6153 | Intra-Cellular | Phase 3 | KRASG12C | |
| Rimabrutinib | Madrigal Pharma | Phase 1/2 | GPRC5D |